# Probingon

> Probingon licenses FAT-IBC, a wireless intrabody communication technology for independent implanted medical devices, to OEM manufacturers in bioelectric medicine. FAT-IBC was developed at Uppsala University's Microwaves in Medical Engineering Group (MMG).

## Core pages

- [Home](https://www.probingon.com/): Overview of Probingon AB and FAT-IBC.
- [Innovation Pipeline](https://www.probingon.com/ipn/): The body-centric technology ecosystem MMG is developing, spanning dielectric sensors, FAT-IBC, brain-computer interfaces, and bionics.
- [Scientific Evidence & Regulatory Outlook](https://www.probingon.com/ipn/science/): Peer-reviewed publications mapped to technology readiness level, and the EU regulatory framework now applying to this technology class.
- [Our Technology Portfolio](https://www.probingon.com/our-technology-portfolio/): Technologies originating from MMG, advanced to TRL 4 at the university and taken to commercial launch by Probingon from TRL 5.
- [FAT-IBC Body Area Networks](https://www.probingon.com/commercialization/fat-ibc-intrabody-communication/): How FAT-IBC removes the colocation constraint limiting today's implantable medical devices.
- [The Near Future of Healthcare](https://www.probingon.com/about-us/the-near-future-of-healthcare/): The shift from episodic to preventive and continuous care in European healthcare, and the infrastructure this shift requires.
- [Commercialization](https://www.probingon.com/commercialization/): Probingon's technology licensing approach.
- [Business Strategy](https://www.probingon.com/about-us/business-strategy/): Probingon's two commercial tracks: technology licensing and selective device development.
- [Mission & Vision](https://www.probingon.com/about-us/mission-vision/): Probingon's mission and long-term vision for closed-loop bioelectric medicine.
- [Our History](https://www.probingon.com/about-us/our-history/): The origin of FAT-IBC at MMG, Uppsala University, and Probingon's founding in 2018.
- [About Us](https://www.probingon.com/about-us/): Company background.
- [Executive Team](https://www.probingon.com/about-us/executive-team/): Probingon's leadership.
- [Investors](https://www.probingon.com/investors/): Information for investors.
- [Services](https://www.probingon.com/services/): Selective consulting and phantom-supply engagements.
- [Clinical Market for MAS](https://www.probingon.com/clinical-market-for-mas/): The clinical problem of muscle atrophy and MMG's muscle-sensing research.
- [News](https://www.probingon.com/news/): Company and research announcements.
- [Contact](https://www.probingon.com/contact/): Contact details.

## Key facts

- FAT-IBC uses subcutaneous fat tissue as a communication channel between implanted and wearable medical devices, without radio frequency emission.
- FAT-IBC was developed at Uppsala University's Microwaves in Medical Engineering Group (MMG), led by Robin Augustine, PhD.
- Peer-reviewed validation of FAT-IBC spans 2017 to 2026, from early channel characterisation through in vivo and human wearable testing. Full record: [Scientific Evidence & Regulatory Outlook](https://www.probingon.com/ipn/science/).
- Robin Augustine (ORCID 0000-0002-2876-223X) has authored over 250 peer-reviewed publications and holds five patents.
- Probingon AB was founded in 2018 in Uppsala, Sweden, as a spin-out from Uppsala University's MMG research group.
- FAT-IBC was selected for the Royal Swedish Academy of Engineering Sciences (IVA) Research Impact List 2026.